HHS quickens pace of Johnson & Johnson COVID-19 vaccine candidate
The Department of Health and Human Services today said it will speed the development and manufacturing of vaccines to prevent COVID-19, starting a candidate from Johnson & Johnson subsidiary Janssen Research & Development.
The agency’s Biomedical Advanced Research and Development Authority will support non-clinical studies and a Phase 1 clinical trial of Janssen’s COVID-19 investigational vaccine, Ad26 SARS-CoV-2. The Phase 1 clinical trial is set to begin no later than fall of 2020 with the goal of making a COVID-19 vaccine available for emergency use in the United States in early 2021.
Related News Articles
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…